77 related articles for article (PubMed ID: 29321441)
1. Improved diabetes control, allowing insulin cessation, after direct acting antiviral treatment (DAAT) of hepatitis C.
Surendran A; Bhalla A; Whyte MB
BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35450872
[TBL] [Abstract][Full Text] [Related]
2. Albumin in hospitalized patients with complications of cirrhosis: Not a suit for all seasons.
Pompili E; Zaccherini G; Caraceni P
Indian J Gastroenterol; 2024 Apr; 43(2):288-291. PubMed ID: 38087187
[No Abstract] [Full Text] [Related]
3. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.
Ji F; Wei B; Yeo YH; Ogawa E; Zou B; Stave CD; Li Z; Dang S; Furusyo N; Cheung RC; Nguyen MH
Aliment Pharmacol Ther; 2018 Mar; 47(5):550-562. PubMed ID: 29327780
[TBL] [Abstract][Full Text] [Related]
4. Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min.
Goel A; Bhadauria DS; Kaul A; Verma P; Mehrotra M; Gupta A; Sharma RK; Rai P; Aggarwal R
Nephrology (Carlton); 2019 Mar; 24(3):316-321. PubMed ID: 29327401
[TBL] [Abstract][Full Text] [Related]
5. Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C.
Scott LJ
Drugs; 2018 Feb; 78(2):245-256. PubMed ID: 29380288
[TBL] [Abstract][Full Text] [Related]
6. Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort.
Álvarez-Ossorio MJ; Sarmento E Castro R; Granados R; Macías J; Morano-Amado LE; Ríos MJ; Merino D; Álvarez EN; Collado A; Pérez-Pérez M; Téllez F; Martín JM; Méndez J; Pineda JA; Neukam K;
J Viral Hepat; 2018 Jun; 25(6):699-706. PubMed ID: 29377515
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection.
Gupta S; Rout G; Patel AH; Mahanta M; Kalra N; Sahu P; Sethia R; Agarwal A; Ranjan G; Kedia S; Acharya SK; Nayak B; Shalimar
J Viral Hepat; 2018 Jul; 25(7):771-778. PubMed ID: 29377464
[TBL] [Abstract][Full Text] [Related]
8. Report from the International Conference on Viral Hepatitis - 2017.
Soriano V; Young B; Reau N
AIDS Rev; 2018; 20(1):58-70. PubMed ID: 29369303
[TBL] [Abstract][Full Text] [Related]
9. All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings.
Berenguer J; Gil-Martin Á; Jarrin I; Moreno A; Dominguez L; Montes M; Aldámiz-Echevarría T; Téllez MJ; Santos I; Benitez L; Sanz J; Ryan P; Gaspar G; Alvarez B; Losa JE; Torres-Perea R; Barros C; Martin JVS; Arponen S; de Guzmán MT; Monsalvo R; Vegas A; Garcia-Benayas MT; Serrano R; Gotuzzo L; Menendez MA; Belda LM; Malmierca E; Calvo MJ; Cruz-Martos E; González-García JJ
Hepatology; 2018 Jul; 68(1):32-47. PubMed ID: 29377274
[TBL] [Abstract][Full Text] [Related]
10. Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital.
Del Rio-Valencia JC; Asensi-Diez R; Madera-Pajin R; Yunquera-Romero L; Muñoz-Castillo I
Rev Esp Quimioter; 2018 Feb; 31(1):35-42. PubMed ID: 29376623
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1.
Ozono Y; Nagata K; Hasuike S; Iwakiri H; Nakamura K; Tsuchimochi M; Yamada Y; Takaishi Y; Sueta M; Miike T; Tahara Y; Yamamoto S; Shide K; Hidaka T; Kubuki Y; Kusumoto K; Ochiai T; Kato J; Komada N; Hirono S; Kuroki K; Shigehira M; Shimoda K
World J Hepatol; 2017 Dec; 9(36):1340-1345. PubMed ID: 29359017
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience.
El-Khayat HR; Kamal EM; El-Sayed MH; El-Shabrawi M; Ayoub H; RizK A; Maher M; El Sheemy RY; Fouad YM; Attia D
Aliment Pharmacol Ther; 2018 Mar; 47(6):838-844. PubMed ID: 29349793
[TBL] [Abstract][Full Text] [Related]
13. Assessing hepatitis C spontaneous clearance and understanding associated factors-A systematic review and meta-analysis.
Aisyah DN; Shallcross L; Hully AJ; O'Brien A; Hayward A
J Viral Hepat; 2018 Jun; 25(6):680-698. PubMed ID: 29345844
[TBL] [Abstract][Full Text] [Related]
14. Risk of Hepatitis B Virus Reactivation Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
Yanny BT; Latt NL; Saab S; Han S; Choi G; Kramer J; Sahota AK
J Clin Gastroenterol; 2018; 52(10):908-912. PubMed ID: 29334502
[TBL] [Abstract][Full Text] [Related]
15. Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study.
Kawano A; Shigematsu H; Miki K; Ichiki Y; Morita C; Yanagita K; Takahashi K; Dohmen K; Nomura H; Ishibashi H; Shimoda S
Intern Med; 2018 Jun; 57(11):1533-1542. PubMed ID: 29321441
[TBL] [Abstract][Full Text] [Related]
16. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
[TBL] [Abstract][Full Text] [Related]
18. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
[TBL] [Abstract][Full Text] [Related]
19. Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1.
Kumari R; Nguyen MH
Expert Opin Pharmacother; 2015 Apr; 16(5):739-48. PubMed ID: 25676581
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
